Retrospective Study
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Feb 24, 2025; 16(2): 98079
Published online Feb 24, 2025. doi: 10.5306/wjco.v16.i2.98079
Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma
Shi-Qiong Zhou, Peng Wan, Seng Zhang, Yuan Ren, Hong-Tao Li, Qing-Hua Ke
Shi-Qiong Zhou, Peng Wan, Seng Zhang, Yuan Ren, Hong-Tao Li, Qing-Hua Ke, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, Hubei Province, China
Co-first authors: Shi-Qiong Zhou and Peng Wan.
Author contributions: Ke QH designed the study; Zhou SQ and Wan P performed the research and wrote the paper, they contributed equally to the manuscript as co-first authors; Li HT and Ren Y contributed new reagents and analytical tools; Zhang S analyzed the data; and all authors approved the submitted manuscript.
Institutional review board statement: The study was approved by the Ethics Committee of the First Affiliated Hospital of Yangtze University (No. KY202428).
Informed consent statement: Exemption from informed consent form was approved by the Ethics Committee of the First Affiliated Hospital of Yangtze University (No. KY202428).
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All datasets during and/or analyzed during the current study are available from the corresponding author upon reasonable request at 3803354759@qq.com.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Hua Ke, Chief Physician, PhD, Department of Chemoradiotherapy, The First Affiliated Hospital of Yangtze University, No. 40 Jinglong Road, Shashi District, Jingzhou 434000, Hubei Province, China. 3803354759@qq.com
Received: June 17, 2024
Revised: October 21, 2024
Accepted: November 25, 2024
Published online: February 24, 2025
Processing time: 176 Days and 21.8 Hours
Core Tip

Core Tip: This study aimed to explore the feasibility and effectiveness of combining the programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine (combination group) vs using S-1 and gemcitabine alone (chemotherapy group) for treating liver metastatic pancreatic adenocarcinoma. The combination of programmed cell death 1 inhibitor sintilimab with S-1 and gemcitabine demonstrated effectiveness and safety for treating liver metastatic pancreatic ductal adenocarcinoma, meriting further investigation.